Originally published March 29.

By Turna Ray

Breast cancer patients with a mutation on chromosome 17 are more likely to see better outcomes from anthracycline treatment than those without the mutation, researchers reported during the European Breast Cancer Conference this week in Barcelona, Spain.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.